NCT06199466View on ClinicalTrials.gov

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

PHASE1TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

September 15, 2025

Study Completion Date

September 15, 2025

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

Gemcitabine

Given by IV

DRUG

Nab-paclitaxel

Given by IV

DRUG

YL-13027

Given by PO

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

280Bio Inc

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER